XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Other Income (Expense)
 12 Months Ended
Dec. 31, 2022
Impact of COVID-19 Pandemic [Abstract]  
Other Income (Expense)
Note 8 – Details of Expenses

The caption “Other” on the accompanying consolidated statements of operations consists of the following:

 
  
Years ended December 31,
  
 
  
2022
    
2021
    
2020
  
 
                  
Foreign exchange gain (loss)
  
$
5,690
    
$
(2,692
)
  
$
(4,095
)
Interest income
    
7,560
      
1,269
      
3,709
  
Other components of periodic pension expense
    
(11,090
)
    
(13,206
)
    
(13,613
)
Investment income (expense)
    
(6,812
)
    
(1,036
)
    
2,271
  
Other
    
(200
)
    
11
      
(26
)
 
  
$
(4,852
)
  
$
(15,654
)
  
$
(11,754
)

The Company used cash to repurchase $151,546 principal amount of convertible senior notes due 2025 in 2020 and recognized a loss on early extinguishment of the repurchased convertible debt of $8,073.

Impact of the COVID-19 Pandemic

The Company's operations have been impacted by the "COVID-19" pandemic, particularly in 2020 when some manufacturing facilities were temporarily closed and some were operating at levels less than full capacity and again in 2022 when operations in the People's Republic of China were impacted by government-mandated shut-downs.  The Company incurred incremental costs separable from normal operations that are directly related to the pandemic containment efforts, primarily wages paid to manufacturing employees during government-mandated shut-downs, additional wages and hardship allowances for working during lockdown periods, additional costs of cleaning and disinfecting facilities, costs of additional safety equipment for employees, and temporary housing for employees due to travel restrictions, which were partially offset by government subsidies.  Since 2021, certain costs directly attributable to the pandemic, such as additional costs of cleaning and disinfecting facility and costs of additional safety equipment for employees, are no longer incremental and are considered normal operating costs.  The net impact of the costs and subsidies are reported as cost of products sold of $6,661 and $4,563 and selling, general, and administrative expenses (benefits) of $546 and $(1,451) based on employee function on the consolidated statements of operations for the years ended December 31, 2022 and 2020, respectively.  

The Company's insurance coverages generally exclude losses incurred due to pandemics.  No amounts have been received due to the pandemic pursuant to the Company's insurance coverages.  Any amounts that may be received in the future will not be recognized until all contingencies are settled.